SEC Info - Sanofi - ‘6-K’ for 9/22/22

Sanofi – ‘6-K’ for 9/22/22

On: Thursday, 9/22/22, at 9:49am ET · For: 9/22/22 · Accession #: 1193125-22-248840 · File #: 1-31368

Current, Quarterly or Annual Report by a Foreign Issuer — Form 6-K — SEA’34

Filing Table of Contents

‘6-K’ — Current, Quarterly or Annual Report by a Foreign Issuer

This is an HTML Document rendered as filed. [ Alternative Formats ]

Dates Referenced Herein

SEC Info℠

Home

Help

Please Sign In

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 9/22/22  Sanofi                            6-K         9/22/22    2:57K                                    Donnelley … Solutions/FA

Document/Exhibit                   Description                      Pages   Size 

 1: 6-K         Current, Quarterly or Annual Report by a Foreign    HTML      9K 
                Issuer                                                           
 2: EX-99.1     Miscellaneous Exhibit                               HTML     41K

6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2022

Commission File Number: 001-31368

SANOFI

(Translation of registrant’s name into English)

54, rue La Boétie, 75008 Paris, FRANCE

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ________

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ________

In September 2022, Sanofi published the press release attached hereto as Exhibit 99.1 which is incorporated herein by reference.

Exhibit Index


Exhibit No.		Description

Exhibit 99.1		Press Release dated September 16, 2022: CHMP recommends approval of Beyfortus® (nirsevimab) for prevention of RSV disease in infants

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: September 22, 2022

/s/ Alexandra Roger

Name: Alexandra Roger

Title: Head of Securities Law and Capital Markets

This ‘6-K’ Filing	Date	Other Filings

Filed on / For Period end:	9/22/22	None on these Dates
		List all Filings

↑Top

Filing Submission 0001193125-22-248840 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)